News

The patents cover composition and methods to target the Ebola virus VP35 protein with a range of PMOplus compounds. The patents have an expiration date of October 31,

This alliance allows speedier product development and helps Applied Protein Sciences (APS) expand its pipeline to develop drugs for mucositis, proctitis and inflammatory bowel disease. APS expects to

The lead compound in this program, RDEA119, is currently being evaluated in advanced cancer patients as a single agent in a Phase I study and in a Phase

Dr Chin is currently the CEO of Institute for OneWorld Health, a nonprofit pharmaceutical company. Dr Chin joined OneWorld Health from OXiGENE, a developer of vascular targeting drugs

From 1999 to 2004, Mr Baledge served as executive vice president and general counsel for Tyson Foods, a multinational food company. Prior to that, Mr Baledge was counsel

According to Power Medical Interventions (PMI), the iDrive Intelligent Power Unit (IPU), a first-of-its-kind breakthrough in operating room instrumentation, is designed to support a variety of minimally invasive

According to Insulet, the OmniPod insulin management system is the first and only continuous insulin delivery system of its kind in the market. The OmniPod system offers people

The Phase I healthy volunteer study of IMX942 will provide human safety and pharmacodynamic data, said Inimex. IMX942 is the first of a new class of drugs known

Existing investors Aescap Venture, Entrepreneurs Fund and Z-Cube also participated in the series B financing. Regina Hodits of Atlas Venture and Deborah Harland of SR One will join